Full Year 2025 Lonza Group AG Earnings Call Transcript
Key Points
- Lonza Group Ltd (LZAGF) achieved strong profitable growth in 2025 with a top-line growth of over 21% in constant exchange rates and an expanding margin to 31.6%.
- The company successfully launched a new operating model in April 2025, enhancing customer experience and operational excellence.
- Lonza's Vacaville site integration was successful, with five large commercial contracts signed, contributing significantly to the company's growth.
- The Advanced Synthesis business showed exceptional performance with a 22% organic growth, driven by bioconjugates and small molecule assets.
- Lonza made significant progress on its sustainability goals, achieving greenhouse gas emission and waste intensity targets five years ahead of schedule.
- The Specialized Modalities platform experienced a decline of 3% in 2025 due to operational challenges in the Cell & Gene business and phasing issues in microbial operations.
- The company faced a 2.5 percentage point negative impact on both top-line and bottom-line due to foreign exchange fluctuations, primarily from a weakening US dollar.
- Despite strong performance, the Integrated Biologics platform saw a slight margin decline due to unfavorable product mix and new asset ramp-ups.
- Lonza's CHI business, which is planned for exit, will be reported as a discontinued operation, indicating potential future restructuring challenges.
- The company anticipates a non-linear path to profitability for the Vacaville site, with expected shutdowns for construction work impacting short-term margins.
(video starts)
(spoken by AI) 2025 was a year of strong growth, robust performance, and significant progress for Lonza. In the first full year of implementing our One Lonza strategy, we outperformed on our targets, while also achieving strategic milestones to further strengthen our position as the world-leading CDMO.
In April, we implemented our new target operating model, built around three business platforms that reflect our sharpened focus on our core CDMO business. This new structure is designed to enhance and strengthen collective and individual accountability, elevate operational excellence, and ensure we are well set up to meet the needs of our customers and their patients.
Turning to our facilities, we are continuing to complete the successful integration of our new Vacaville site by adding people, capacities, and capabilities. Here, we have already signed a number of large commercial contracts and continue to invest into the site's CDMO offering whilst improving flexibility to unlock its significant growth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
